RET and neoplasm: Of interest, calcitonin levels decreased dramatically after vandetanib therapy, but the marker decrease did not directly correlate with changes in tumor volume; thus, calcitonin may not be a reliable marker of tumor response in patients receiving RET inhibitor therapy [37].